Board of Directors
Carl Borrebaeck (1948), Chairman
Professor Carl Borrebaeck is a successful serial entrepreneur, having co-founded Immunovia AB, Senzagen AB (SENZA; Nasdaq First North), BioInvent International AB (BINV: Stockholm) and Alligator BioScience AB (ATORX; Nasdaq Stockholm). Prof. Borrebaeck is a 2009 recipient of the AkzoNobel Science Award and was awarded the 2012 Gold Medal from the Royal Academy of Engineering Sciences in recognition of his ground-breaking research regarding biomarkers. In 2017 he was designated as the Biotech builder of the Year for his entrepreneurship. In addition, Prof. Borrebaeck is previously the Vice-President of Lund University, Sweden (responsible for its Innovation systems); and currently Director of CREATE Health, a Translational Cancer Center; and previously chairman of the Department of Immunotechnology. Carl Borrebaeck is also a founding mentor for NOME (Nordic Mentor Network for Entrepreneurship).
Immunovia has entered into an agreement with CB Ocean Capital AB regarding services to be provided by Carl Borrebaeck. Carl Borrebaeck shall provide services aimed at providing scientific and strategical support to the Company, for example at scientific presentations and conferences. The services provided do not include tasks that belongs to his board assignment. According to the agreement, CB Ocean Capital AB receives a remuneration of SEK 31,500 each quarter, excluding social fees and VAT. The agreement is valid from 1 January 2018 until further notice, with a mutual three-month notice period.
Current board appointments: Chairman of the Board of Senzagen AB and Ocean Capital AB. Member of the Board of Alligator Bioscience AB, Clinical Laserthermia Systems AB and Scandion A/S. Carl Borrebaeck is also partner of Immunova Handelsbolag.
Completed appointments (last five years): Carl Borrebaeck has been Chairman of the Board of LU Innovation System AB. He has been Member of the Board of Atlas Therapeutics AB, BioInvent International AB, LU Holdings AB, Medicon Village Fastighets AB and WntResearch AB. He has also been Deputy Director of Endo Medical AB.
Ann-Christine Sundell (1964)
Ann-Christine Sundell has a MSc in biochemistry and more than 30 years of experience from the medical device industry, she has held various global positions. For 10 years she served as president for Genetic Screening, one of five strategic business areas with over 1500 employees worldwide within PerkinElmer, one of the world’s largest Life Science companies.
Ann-Christine has strategic and operational experience from areas where Immunovia is active such as Sales & Marketing, R&D, production, quality and compliance.
Current board appointments: Chairman of the Board of Oy Medix Biochemica Ab and Serres Oy. Vice Chairman of Raisio Oyj. Board Member of Ab Archipelagia Golf Oy, BluePrint Genetics Oy, Ledil Group OY, Ledil Oy, Minervastiftelsen, Oy Medix Ab and Revenio Group Oyj. Committee Member of Raisio Oyj’s Research Foundation and holder of AConsult.
Completed appointments (last five years): Chairman of the Board of Oy Medix Biochemica Ab. Board member of the Minervastiftelsen, Oy Medix Ab, Vanadis Ab and Zymonostics ApS.
Hans Johansson (1954)
Hans Johansson has a MSc in Chemical Engineering and excessive experience and a wide network from his previous positions in Life Science and Diagnostics companies, lately as VP, Head of Companion Diagnostics at ThermoFisher Inc Speciality Diagnostics Group.
Hans Johansson was also a former VP of Global Marketing and Commercial Development within the same company but at the ImmunoDiagnostics division and earlier VP, Head of the Laboratory Business Unit at Pharmacia Biotechnology.
Hans Johansson has also been an active entrepreneur as CEO/Boardmember in the life science sector. Altogether, he has 30 years of experience from global business development and commercialization of biotechnical and diagnostic innovations.
Current board appointments: Chairman of the Board of Doloradix AB and Myrtila AB. He has been a Board Member of Single Technologies AB and Uppsala Innovation Centre AB.
Completed appointments (last five years): He has been Deputy Director of Duvbo Affärskonsult AB.
Peter Høngaard Andersen (1956)
Dr. Peter Høngaard Andersen has a B.Sc. in Chemistry, a M.Sc. in Biochemistry, is Doctor of Medicine and have excessive experience and a wide network from his previous positions in Life Science and the biotech industry.
Dr. Høngaard Andersen has extensive drug discovery and development experience from Pharma; 14 years from Novo Nordisk in CNS, neuroendocrinology, women health, type 2 diabetes and 15 years at Lundbeck in CNS drug discovery and early development. Dr. Høngaard Andersen has been involved in the discovery and development of several drugs on the market (e.g., Norditropine Simplex, Victoza, Trintellix/Brintellix, Cipralex).
Dr. Høngaard Andersen has founded or co-founded several biotech companies e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics and Prexton Pharmaceuticals.
Dr. Høngaard Andersen was involved in Innovative Medicines Initiative (IMI) from the beginning in 2003 and was chairing the industry side of IMI from 2009 – 2014.
Current board appointments: Chairman of the Board of Scandion Oncology A/S and the Innovation Board in the Association of Danish Regions and member of the board in Immunovia AB. In addition, Dr Høngaard Andersen is member of the advisory boards in Ysios Capital and Eir Ventures.
Completed appointments (last five years): Founder and has been Managing Director of Innovation Fund Denmark, Member of the Executive Committee of the IC Permed (the International Consortium of Personalized Medicine) and Chairman of Prexton Therapeutics.
Christofer Sjögren (1966)
Christofer Sjögren has 15 years of experience in the financial industry as equity analysts in companies like Carnegie, Danske Bank (publ) and Deutsche Bank (publ) based in Stockholm. Christofer Sjögren has also been an Investor Relations consultant at Citigate Stockholm (formerly part of Huntsworth plc), and has been Vice President of Trelleborg AB (publ) for seven years as Head of Trelleborg Investor Relations.
Current board appointments: Board member Trelleborg Group Treasury.
Mimmi Ekberg (1959)
Mimmi Ekberg has almost 30 years of experience of from the Pharmaceutical industry and 25 years within the oncology disease area. She has held different National and Nordic positions with experience of successful launches of specialist products. Mimmi has extensive strategic and operational experience within Sales & Marketing for different indications in the Oncology area. She has experience as Business Unit Manager from E. Merck, Amgen and currently serves as the Business Unit Manager Oncology Nordic at Celgene, with a special focus on pancreatic cancer. Mimmi is educated as an Operating room nurse with various additional educations as Medical Oncology from Lund University, Clinical trials in Oncology Karolinska University hospital, and Executive Master of Business Administration from Stockholm University.
Completed appointments (last five years): Founder and board member of Anhörigfonden.